-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – APH-0812 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APH-0812 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APH-0812 in Human Immunodeficiency Virus (HIV) Infections (AIDS)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Endoxifen in Ductal Carcinoma In Situ
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Endoxifen in Ductal Carcinoma In Situ report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Endoxifen in Ductal Carcinoma In Situ Drug Details: Endoxifen is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tigilanol Tiglate in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tigilanol Tiglate in Soft Tissue Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tigilanol Tiglate in Soft Tissue Sarcoma Drug Details: Tigilanol tiglate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Endoxifen in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Endoxifen in Ovarian Cancer Drug Details: Endoxifen is under development for the treatment of HER2...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APH-0812 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.APH-0812 in Human Immunodeficiency Virus (HIV) Infections (AIDS) Drug Details:APH-0812 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tigilanol Tiglate in Laryngeal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tigilanol Tiglate in Laryngeal CancerDrug Details:Tigilanol tiglate (EBC-46) is under development for the treatment of refractory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tigilanol Tiglate in Salivary Gland Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Tigilanol Tiglate in Salivary Gland Cancer Drug Details:Tigilanol tiglate (EBC-46) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tigilanol Tiglate in Paranasal Sinus And Nasal Cavity Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tigilanol Tiglate in Paranasal Sinus And Nasal Cavity CancerDrug Details:Tigilanol tiglate (EBC-46) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tigilanol Tiglate in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tigilanol Tiglate in Metastatic Colorectal CancerDrug Details:Tigilanol tiglate (EBC-46) is under development for the treatment of...
-
Company Profile
Ideaya Biosciences Inc – Company Profile
Ideaya Biosciences Inc (Ideaya) is a precision medicine company that develops oncology therapeutics. The company’s product pipeline includes darovasertib (IDE196), a protein kinase C (PKC) inhibitor that targets cancers with GNAQ and GNA11 mutations. It develops small molecule inhibitors based on synthetic lethality against known and novel targets. Ideaya also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). The company collaborates with Novartis Institute for Biomedical Research, Pfizer Inc, Boston Children’s...
Add to Basket